Repligen | RGEN - أصول متداولة





أصول متداولة تغيير تاريخ
Agilent USD 4.62B 21M 2025-12
Align Technology USD 2.66B 38.87M 2026-03
Bio Techne USD 688.05M 50.62M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Bruker USD 2.1B 108.9M 2026-03
Charles River Laboratories USD 1.49B 41.76M 2026-03
Danaher USD 13.94B 1.18B 2026-03
Dentsply International USD 1.85B 178M 2026-03
General Electric Aerospace USD 40.36B 235M 2026-03
Henry Schein USD 4.5B 32M 2026-03
Illumina USD 2.74B 551M 2026-03
IQVIA Holdings USD 6.22B 29M 2026-03
Mettler Toledo International USD 1.36B 81.46M 2025-12
Myriad Genetics USD 312.8M 19.8M 2026-03
OraSure Technologies USD 261.91M 21.1M 2025-12
Pacific Biosciences Of California USD 375.05M 19.18M 2025-12
Pfizer USD 42.82B 76M 2026-03
Repligen USD 1.16B 23.98M 2026-03
Revvity USD 2.13B 111.43M 2026-03
Standard Biotools USD 521.45M 67.19M 2026-03
Thermo Fisher Scientific USD 22.32B 6.39B 2026-03
Waters USD 3.72B 1.73B 2026-03
West Pharmaceutical Services USD 1.83B 151.4M 2026-03